Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada

 Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada

Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada

Shots:

  • STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of profits from sales of the biosimilar. The companies aim to obtain all currently approved indications for Lucentis in the US and Canada
  • Xbrane and STADA will finalize the development of the Xlucane with Xbrane providing the commercial supply. Following regulatory approval, Bausch + Lomb will be responsible for marketing and commercialization of the biosimilar in the US and Canada
  • The addition of biosimilar candidate to Lucentis (ranibizumab) to Bausch + Lomb’s portfolio will expand its ophthalmic portfolio. Under the collaboration, STADA and Xbrane will leverage Bausch + Lomb’s expertise in the North American ophthalmic market

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bausch + Lomb

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post